首页> 美国卫生研究院文献>Journal of Primary Care Community Health >We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity
【2h】

We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity

机译:我们应该为基于循证的危险因素提供更多的循证治疗以便Covid-19:肥胖

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France show odds ratio (OR) of 2.31 (95% CI 1.3-4.1) for obesity and severe COVID-19. Other studies show OR of 12.1 (95% CI 3.25-45.1) for mortality and OR of 7.36 (95% CI 1.63-33.14) for need for IMV for patients with body mass index (BMI) ≥ 35 kg/m2. Obesity is the only modifiable risk factor that is not routinely treated but treatment can lead to improvement in visceral adiposity, insulin sensitivity, and mortality risk. Increasing the awareness of the association between obesity and COVID-19 risk in the general population and medical community may serve as the impetus to make obesity identification and management a higher priority.
机译:来自多个国家的观察研究反复展示肥胖和严重的Covid-19之间的关联,其被定义为住院治疗,重症监护单元入院,侵入性机械通气(IMV)或死亡。中国,美国和法国研究的荟萃分析显示肥胖和严重Covid-19的2.31(95%CI 1.3-4.1)的赔率比(或)。其他研究表明或12.1(95%CI 3.25-45.1)的死亡率和7.36(95%CI 1.63-33.14),适用于体重指数(BMI)≥35kg/ m2的患者的IMV。肥胖是唯一不常规治疗的可修改的危险因素,但治疗可以导致内脏肥胖,胰岛素敏感性和死亡率风险的提高。提高肥胖与Covid-19在一般人口和医学界的风险之间的协会的认识可以作为使肥胖识别和管理更高优先级的推动力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号